 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Interleukin
See also: Research on Immune-Based Therapies
Overview
- The Development Pipeline for Cytokines, Immunomodulators and Gene Therapy (September 29, 2005)
In TAGline, from Treatment Action Group - IL-2: Promiscuous Cytokine or Steady Date? (Winter 2001/2002)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America - The Role of IL-10 in Long-Term Non-Progressors (Winter 2001/2002)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America - What's New With IL-2? (January 2001)
In Hopkins HIV Report
Open Trials
- Interleukin-2: SILCAAT Study to Continue (October 2003)
To read PDF, click here
In Project Inform Perspective, from Project Inform - Company Backs Out of Immune Drug Study (November 1, 2002)
From Canadian AIDS Treatment Information Exchange
Trial Results
- Interleukin-2 Ineffective in Maintaining Baseline CD4+ Cell Count During Treatment Interruption (February 6, 2008)
From The Body PRO - TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Interleukin-2 Expands Select CD4+ T-Cell Populations, but Has No Effect on HIV-Specific Immune Responses (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Scientists Explore Possible New Way to Fight AIDS (February 8, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Comparing a Treatment Interruption With or Without Interleukin-2 in Delaying a Falling CD4+ Cell Count (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - HIV Patients Get Long-Term Boost With Short, Intermittent Drug Regimen (April 26, 2004)
From U.S. National Institute of Allergy and Infectious Diseases - Immunological and Virological Efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) Combined With SC IL-2 in Chronically HIV-Infected Patients -- Results of the ANRS 093 Randomized Study (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - IL-2 & CD4 T Cells: Number & Function Disconnect? (January/February 2003)
In TAGline, from Treatment Action Group - Interleukin-2 (IL-2, Proleukin) and Immune Function (January 2003)
Research from the 2002 International AIDS Conference.
To read PDF, click here
In Project Inform Perspective, from Project Inform - Setback for Validation of IL-2 (November 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis - Baseline Characteristics Associated With CD4+ Response After Three Cycles of Subcutaneous (SC) Recombinant Human Interleukin-2 (IL-2) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Intermittent IL-2 Administration in HIV Infected Patients Leads to a Decrease in CD4+ T Cell Turnover Rates (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Interleukin-2 Improves CD4+ Cell Counts in Patients with Poor Immune Response to HAART (April 2001)
In HIV Treatment Bulletin - Experimental Immune Modulator Drugs (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - A Randomized Trial of Interleukin-2 (IL-2) Added to HAART for Primary HIV (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Extended Therapy with Subcutaneous Interleukin-2 (scIL-2) in HIV-Infection: Long-Term Follow-Up of 3 Trials (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Immunomodulation of Chronic HIV-1 Infection: Impact of HAART, Interleukin-2 and/or an Inactivated gp120-Depleted HIV-1 Immunogen (REMUNE) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prediction of CD4+Cell Response to Subcutaneous Recombinant Interleukin-2 (SCrIL-2) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective, Randomized, Controlled Phase II Study of Highly Active Antiretroviral Therapy (HAART) with Continuous IV (CIV) or Subcutaneous (SC) Interleukin-2 (IL-2) in HIV-Infected Patients with CD4+Counts of 50 -- 350 cells/mm3: ACTG 328 -- Final Result (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |